Carolina BioOncology Institute | Huntersville, NC
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Dose-Escalation:
Dose-Expansion:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
150 participants in 7 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal